HLB Pharmaceutical

At a glance

HLB Pharmaceutical filed 64 disclosures in the last 12 months, including 12 5% holder, 5 insider and 1 issuance. The most recent key filing was on Oct 21: A major holder's stake rose from 18.97% to 18.97% (pledge).

Revenue for 2025 was ₩206B, up 50% on 2024. Operating margin was 0.5% against 1.1% a year earlier. Debt was 36% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩128B and operating profit of ₩1B.

The 2025 annual report lists 185 employees with an average tenure of 4.3 years and average pay of ₩54M, #1264 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩85.5M each on average. It paid no cash dividend for 2025. 에이치엘비생명과학㈜ and related parties held 20.94% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 18.97% on Oct 21.

From the 2025 annual report

Staff: 185 (93 men, 92 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩10B. Directors and auditors: 7, paid ₩598.2M in total.

No cash dividend was paid for 2025.

Largest shareholder

에이치엘비생명과학㈜ holds 16.15%; with 5 related parties the group holds 20.94% of common shares at year end (from 18.52% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Rankings: Revenue growth #52 of 1,376

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports